Carlos Tutau Gómez

Carlos Tutau Gómez

Auto-generated profile, based on publicly available information

Carlos Tutau Gómez

Cystic Fibrosis Unit Hospital Universitario de Cruces Barakaldo Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2025 in JPGN Reports
Verified
Journal Article
Open access
ECElena Crehuá-Gaudiza
Elena Crehuá-Gaudiza
SVSaioa Vicente
Saioa Vicente
MBMarina Álvarez Beltrán
Marina Álvarez Beltrán
CFCarmen Martín Fernández
Carmen Martín Fernández
CGCarlos Tutau Gómez
Carlos Tutau Gómez
DJDavid Gonzalez Jimenez
David Gonzalez Jimenez
This is a prospective, multicenter study of a cohort of 224 cystic fibrosis (CF) patients treated with CF transmembrane conductance regulator (CFTR) modulators (CFTRm). Our aim was to prospectively analyze the effect of CFTRm treatment on fat‐soluble vitamin serum levels. Demographic and clinical data were recorded, and fat‐soluble vitamin levels were analyzed at baseline, and at 6 and 12 months after starting treatment. Two groups were analyzed separately: patients receiving dual therapy lumacaftor/ivacaftor or tezacaftor/ivacaftor (Lum/Tez+Iva), and those on triple therapy with elexacaftor/tezacaftor/ivacaftor (ETI). We found that treatment with ETI produced a significant increase in vitamin D and A levels within the first 6 months, which was maintained at 12 months. However, with dual therapy, we observed an increase only in vitamin A levels within the first 6 months, which was not maintained at 12 months. No differences were found in vitamin E serum levels between the groups.